Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 3/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 4/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275037 | 0.91 | TDP1 (0.50) | CACNA1HCACNA1BTDP1MAPK14PTGDR2 | |
| SCHEMBL3273823 | 0.91 | CACNA1H (0.55) | CACNA1HCACNA1BTDP1PTGDR2MAPT | |
| SCHEMBL3047854 | 0.91 | PTGDR2 (0.57) | CACNA1HCACNA1BTDP1PTGDR2CCR2 | |
| SCHEMBL3274410 | 0.89 | CACNA1H (0.58) | CACNA1HCACNA1BTDP1MAPK14PTGDR2 | |
| SCHEMBL3050536 | 0.87 | CACNA1H (0.62) | CACNA1HCACNA1BTDP1CCR2CCR1 | |
| SCHEMBL3280640 | 0.83 | CACNA1H (0.52) | CACNA1HCACNA1BMAPK14CCR2 | |
| SCHEMBL3049521 | 0.82 | POLB (0.53) | CACNA1HCACNA1BTDP1PTGDR2CCR2 | |
| SCHEMBL3274441 | 0.82 | CCR2 (0.50) | PTGDR2CCR2CCR1MAPT | |
| Hydrochloric Acid SCHEMBL3050435 | 0.81 | CACNA1H (0.48) | CACNA1HCACNA1BCCR2 | |
| SCHEMBL3045528 | 0.81 | TDP1 (0.54) | CACNA1HCACNA1BTDP1PTGDR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CACNA1H 997/4885CACNA1B 915/4885TDP1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.